Balversa ^*

This text is for informational purposes only. Please consult a doctor or pharmacist before using any medication.

Read the information leaflet that comes with the medication.

Most people who use Balversa do not experience any negative side effects. Doctors prescribe Balversa because they assess that the benefits that such treatment yields outweigh any likely unwanted effects.

There is the possibility that eye problems that are common during treatment with Balversa can become serious. These include dry or inflamed eyes, inflamed cornea and disorders of the retina (the back of the eye). Tell a doctor right away if blurred vision, loss of vision or other visual changes develop.

Some common side effects of Balversa tablets include

• Problems such as dryness or inflammation of the retina or other parts of the eye, resulting in symptoms such as blurring of vision, vision changes, or loss of vision
• Increase in phosphate levels in the blood hyperphosphatemia
• Mouth sores
• Unusual tiredness
• Impairment of kidney functions
• Dry mouth
• Low sodium levels reduce appetite
• Nail deformity, such as separation of the nails from the bed
• Change in the sense of taste
• Low blood cell counts.

Balversa can be prescribed for the management of locally advanced and metastatic carcinoma of the bladder. It is specifically used for treating urothelial carcinoma, which occurs as a result of abnormal changes in certain genes.

Balversa has been shown as being able to shrink a tumor of the bladder or stop the spread of cancer to make surgery less invasive and more effective when the bladder carcinoma has progressed during or following at least one line of therapy.

It is also recommended as a part of the post-operative therapy period for patients who undergo surgical intervention for the removal of the cancer mass.

Balversa can help in the management of urothelial carcinoma by targeting certain proteins in the cancer cells. This prevents the growth of cancer cells and limits the spread of abnormal cells to other organs. Balversa might significantly improve the prognosis of patients and even lower the chances of relapse.